What Traferox Technologies does

Traferox Technologies Inc. is a privately held Canadian medical device company founded in 2021 as a spin-out from University Health Network's Toronto General Hospital to commercialize organ preservation and perfusion technologies. The company designs, manufactures, and sells two core product lines: the X°Port Lung Preservation System, which uses a proprietary phase change material to maintain donor lungs at 10°C for up to 24 hours (versus ~6 hours on traditional ice), and the TorEx Lung Perfusion System, which is the only ex vivo lung perfusion (EVLP) platform purpose-built for the Toronto Technique — the EVLP strategy with the largest installed clinical base globally. Supporting consumables include the X°Port Lung Preservation Solution and the cGMP-manufactured TorEx Lung Perfusate, and the company has extended the X°Port platform into heart preservation. FDA approval for X°Port landed in 2025; TorEx is Health Canada-approved and used clinically in Europe but is not yet authorized in the United States.

Traferox serves hospital transplant centers performing lung (and increasingly heart) transplantation, addressing the well-documented problem that only ~20% of donor lungs are currently accepted for transplant while ~10,300 patients sit on global lung transplant waitlists. Its technology is rooted in decades of UHN research led by co-founders Dr. Shaf Keshavjee (CMO) and Dr. Marcelo Cypel (CSO), the inventors of the Toronto Technique, and is commercialized by a management team with a track record of scaling NOVADAQ Technologies to a $700M+ sale to Stryker.

The business model combines one-time capital equipment sales (X°Port units estimated at ~$10,000 each) with recurring single-use consumables (disposable coolers, perfusate) sold via direct enterprise field sales to licensed transplant programs. The company distributes globally with active clinical adoption across five continents, anchored by reference customers including Toronto General Hospital, Duke, Cleveland Clinic, and Mayo Clinic, and supported by a 300-patient EU clinical trial in Austria and Spain. A February 2025 FedDev Ontario grant funds manufacturing capacity expansion as the company scales toward US commercialization.

Name

Traferox Technologies

Legal name

Traferox Technologies Inc.

Website

https://traferox.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Traferox Technologies is a Canadian medical device company that designs and sells organ preservation (X°Port) and ex vivo lung perfusion (TorEx) systems to hospital transplant centers, enabling 10°C preservation and the Toronto Technique EVLP for lung and heart transplantation.

Ownership category

akta.pro rank

Product category

Organ Transplantation Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies (HLAAAJAN)

Keywords

• Organ preservation devices
• Lung perfusion systems
• Transplant medical devices
• Ex vivo lung perfusion
• Organ transport equipment

Headquarters

HQ city

Mississauga

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales (Capital Equipment): Sale of X°Port and TorEx organ preservation and perfusion systems to transplant hospitals. Each X°Port unit estimated at $10,000. Devices require regulatory approval and are sold directly to licensed healthcare institutions.
2. Disposable/Consumable Products: Disposable coolers and single-use components for organ transport and perfusion procedures. Disposable cooler products referenced as part of product portfolio.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Traferox Technologies designs, manufactures, and sells organ preservation and perfusion medical devices for lung and heart transplantation. Its core products include the X°Port Lung Preservation System (10°C static cold preservation using proprietary phase change material) and the TorEx Lung Perfusion System (Ex Vivo Lung Perfusion via the Toronto Technique), along with proprietary perfusate and preservation solutions. The company also offers the X°Port Heart Preservation System for extended heart preservation.

Product overview

Traferox Technologies offers a portfolio of organ preservation and perfusion systems focused on 10°C temperature management for transplantation. The core offerings include the X°Port Lung Preservation System (with X°Port Lung Preservation Solution) for storing and transporting donor lungs at 10°C, and the TorEx Lung Perfusion System (with TorEx Lung Perfusate) for ex vivo lung assessment using the Toronto Technique of EVLP. The company also offers the X°Port Heart Preservation System for heart preservation at 10°C. These products work together to extend organ viability windows, enable longer transport distances, and allow assessment of marginal donor organs that would otherwise be discarded.

Differentiator

Problem solved

Functional benefit

Brands

• X°Port: Lung Preservation System with X°Port Lung Preservation Solution for storage, preservation, and transport of donor lungs at 10°C.
• TorEx

Products and services

• X°Port Lung Preservation System A medical device system for storage, preservation, and transport of donor lungs at 10°C. Uses proprietary phase change material and insulating foam to maintain temperature between 4–10°C. Features a Bluetooth-connected temperature logger and mobile app for continuous organ monitoring. Sold to hospital transplant centers.
• X°Port Lung Preservation Solution (XLS) A low-potassium, dextran-based lung preservation solution designed for cold flush and static storage of donor organs. Protects endothelial integrity and minimizes cellular edema during transport and pre-transplant organ handling. Sold as a consumable to transplant hospitals.
• TorEx Lung Perfusion System The only EVLP system designed for the Toronto Technique, enabling continuous normothermic machine perfusion of donor lungs with unknown function for ex vivo functional assessment prior to transplantation. Features plug-and-play chamber, compact design, and multifaceted assessment of lung function. Sold to hospital transplant centers.
• TorEx Lung Perfusate (TLP) A cGMP-manufactured, sterile solution for ex vivo lung perfusion. Supports fluid balance and metabolic activity at 37°C during normothermic lung assessment procedures. Sold as a consumable to transplant hospitals.
• X°Port Heart Preservation System A medical device system for heart preservation at 10°C, enabling extended preservation times compared to traditional ice storage (4–6 hours). Uses proprietary phase change material and insulating foam with a heart cradle for transport protection. Sold to hospital heart transplant programs.

Quantifiable outcome

• Lungs stored at 10°C transplanted after 24 hours with no increase in complication rates vs 6-hour storage at 4°C (Annals of Surgery, 2025)
• +6 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core and major.

• University Health Network (UHN) / Toronto General HospitalcoreStrategic or Co-development Partner · 1 January 2025Traferox was founded in 2021 as a spin-out from UHN's research program. The company's technology (X°Port and TorEx) was invented at UHN's Latner Thoracic Surgery Research Laboratories by Dr. Shaf Keshavjee and Dr. Marcelo Cypel. UHN remains the primary clinical site and the source of ongoing research collaboration.
• Duke University Hospital, Cleveland Clinic, Mayo ClinicmajorStrategic or Co-development Partner · 1 January 2024Leading US transplant centers using the Toronto Ex Vivo Lung Perfusion System (EVLP/TorEx). These institutions represent early clinical adopters and reference sites for the technology. The EVLP system is used in hospitals on five continents.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Medtronic: Large diversified medtech with ECMO, oxygenators and mechanical circulatory support products used in transplant ICUs and ORs. Adjacent incumbent that could extend into organ preservation/perfusion as an integrated offering.

Others

• Bridge to Life: Supplier of organ preservation solutions (UW, HTK, Custodiol) used by transplant centers globally. Adjacent competitor on the consumable side, particularly relevant to Traferox's preservation solution strategy.
• Preservation Solutions: US manufacturer of UW, Euro-Collins and Custodiol HTK preservation solutions. Competes with Traferox's preservation solution consumables as a long-standing incumbent in transplant center formularies.
• Institut Georges Lopez (IGL): European developer of static preservation solutions (Celsior, SCOT, etc.) widely used in thoracic and abdominal organ preservation. Adjacent competitor on preservation solutions and a natural strategic or distribution partner.

Direct peers

• TransMedics: Publicly traded US medtech company developing the Organ Care System (OCS) platform for lung, heart and liver — the closest direct competitor to Traferox across both preservation and normothermic perfusion of multiple organs, and the most relevant public-market comparable.
• OrganOx: UK-based medtech company commercializing the metra system for normothermic liver perfusion. Direct peer in ex vivo organ perfusion technology and product architecture, although focused on liver rather than lung.
• Paragonix Technologies: US medtech company commercializing the SherpaPak cardiac transport system and expanding into kidney and liver preservation. Direct peer in organ preservation/transport hardware and disposables, particularly relevant to Traferox's X°Port Heart product.
• XVIVO Perfusion: Publicly traded Swedish medtech company whose XPS system is the dominant non-Toronto EVLP platform and whose Perfadex solution is a leading lung preservation product. Direct competitor in lung EVLP and the strongest European head-to-head.
• Organ Recovery Systems: US company behind the LifePort Kidney Transporter, the leading ice-based preservation platform for kidney transplantation. Direct peer in organ preservation hardware, with overlapping hospital customers in the transplant space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/TraferoxTech
• LinkedInlinkedin.com/company/traferox

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Traferox Technologies